TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

Leukemia

Volumn 13, Issue 11, 1999, Pages 1817-1824

  Gazitt, Y ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apoptosis; bcl 2; Myeloma; TRAIL

Indexed keywords

CD34 ANTIGEN; METHYLCELLULOSE; PROTEIN BCL 2; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BURST FORMING UNIT E; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0032717188     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401501     Document Type: Article

References (40)

1. Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 1996; 16: 87-103.
2. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
3. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
4. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
5. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda M, Tsujimoto Y. Involvement of CPP32/Yama-like proteases in Fas-mediated apoptosis. Cancer Res 1996; 56: 1713-1718.
6. Wiely SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicoll JK, Sutherland GR, Smith TV, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
8. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin ZM. Intracellular regulation of TRAIL-induced apoptosis in human melanoma. J Immunol 1998; 161: 2833-2840.
9. Beg A, Baltimore D. An essential role for NF-κB in the prevention of TNF-α-induced apoptosis. Science 1996; 274: 782-784.
10. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of JNK kinase and p38 kinase regulates cell survival in response to tumor necrosis factor α. J Biol Chem 1998; 273: 1032-1039.
11. Marsters SA, Sheridan JP, Donahue J, Pitti RM, Gray CL, Goddard AW, Bauer D, Ashkezazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol 1996; 6: 1669-1676.
12. Takayama S, Cazals-Hatem DL, Kitada S, Tanaka S, Miashita T, Hovey RL, Huen D, Rickinson A, Veerapandian P, Krajewski S, Saito K, Reed JC. Evolutionary conservation of function among mammalian, avian, and viral homologs of the bcl-2 oncoprotein. DNA Cell Biol 1994; 13: 679-692.
13. Krajevski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 1993; 53: 4701-4714.
14. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
15. Reed JC, Kitada S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994; 5: S61-S65.
16. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of bcl-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994; 8: 1960-1969.
17. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in human leukemia cell line. Blood 1994; 81: 151-157.
18. Reed JC. Bcl-2 and programmed cell death. J Biol Chem 1994; 124: 1-6.
19. Sentman CL, Shutter JR, Hokenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.
20. Debatin K-M, Krammer PH. Resistance to APO-1 (CD95)-induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia 1995; 9: 815-820.
21. Rodriguez I, Matsuura K, Reed JC, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not rapid death induced by anti-Fas antibody injection. J Exp Med 1996; 183: 1031-1036.
22. Strasser A, Harris AW, Huang D, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulates distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14: 6136-6147.
23. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633-2643.
24. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621-627.
25. Tian E, Gazitt Y. The role of P53, bcl-2 and bax in dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 1996; 8: 719-726.
26. Hu W-X, Gazitt Y. Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 1996; 9: 375-381.
27. Tian E, Hu W-X, Gazitt Y. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in multiple myeloma cell lines: a study with inducible bcl-2 transfection construct. Int J Oncol 1996; 9: 165-169.
28. Gazitt Y, Rothenberg ML, Hilsenbeck S, Fey V, Thomas C, Montgomery W. Bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines. Int J Oncol 1998; 13: 839-848.
29. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone but not melphalan in multiple myeloma cell lines. Int J Oncol 1998; 13: 397-405.
30. Gazitt Y, Hu W-X. Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: a study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines. Int J Oncol 1998; 12: 211-220.
31. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood 1994; 84: 3063-3070.
32. Gazitt Y, Erdos GW. Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res 1994; 54: 950-956.
33. + cells do no contain myeloma cells. Blood 1995; 86: 381-389.
34. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AW, Godowsi P, Ashkezazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
35. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.
36. Adams JM, Cory S. The bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1325.
37. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin A, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Sch JCL, Lynch DH. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing activity. Nature Med 1999; 5: 157-163.
38. Mariani SM, Matiba B, Armadola EA, Krammer PH. Interleukin-1 beta converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997; 137: 221-229.
39. Gazitt Y, Freytes C, Callander N, Tsai T-W, Alsina M, Anderson J, Holle L, Cruz J, Devore P, McGrath M, West G, Alvarez R, Montgomery W. Successful peripheral blood stem cell mobilization with high dose G-CSF for patients failing first round of mobilization. J Hematother 1999; 8: 173-183.
40. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis induced by TRAIL and TNFα in human multiple myeloma cells is not blocked by bcl-2. Cytokine 1999 (in press).